Abstract: This invention relates to novel vectors and host cells containing nucleic acids coding for a polypeptide having thrombin binding ability, anticoagulant activity and thrombolytic activity. The polypeptide can be efficiently produced in large quantities by means of genetic recombination techniques using the vectors and host cells of the present invention. Since the polypeptide exhibits anticoagulant activity and thrombolytic activity without generating side effects such as bleeding tendencies, it can be applied effectively to the prevention and treatment of hypercoagulability-related diseases.

Abstract: A simplified measuring apparatus for use in the qualitative or quantitative measurement of substances to be assayed in test samples, such as proteins, antibodies and the like, in a small amount of test samples by a simple and easy operation without requiring a B/F separation step comprises: (a) a liquid permeable porous reaction membrane whose surface having at least one reaction area to which an affinity substance capable of directly or indirectly capturing a substance to be assayed or a soluble agent is immobilized; (b) a porous body arranged on the upper part of the porous reaction membrane, to which a soluble agent capable of being solubilized by the addition of a test sample is adhered in a releasable manner; (c) an absorption member arranged on the lower part of the porous reaction membrane, which contacts with a periphery, excluding the reaction area, of the porous reaction membrane via a liquid non-permeable sheet; (d) a liquid non-permeable transparent cover arranged on the lower part of the absorpti

Abstract: This invention relates to a novel polypeptide which is obtained by means of genetic recombination DNA techniques and has thrombin binding ability, anticoagulant activity and thrombolytic activity. The polypeptide of the present invention can be produced in a large quantity and efficiently by means of genetic recombination techniques. Since the polypeptide of the present invention exhibits anticoagulant activity and thrombolytic activity without generating side effects such as bleeding tendency, it can be applied effectively to the prevention and treatment of hypercoagulability-related diseases.

Abstract: A reagent for use in an immunoassay for measuring haptens, antigens or antibodies by means of a competitive binding method, which comprises a combination of an antibody and a labelled hapten or a labelled antigen or a combination of a hapten or an antigen and a labelled antibody, wherein the antibody and the labelled hapten or the labelled antigen in one combination or the hapten or the antigen and the labelled antibody in another combination are capable of undergoing reversible binding, and a device for use in an immunoassay wherein the reagent of the present invention is included in a single container.An immunoassay can be performed in a short time by the use of the immunoassay device of the present invention.

Abstract: This invention relates to a novel anticoagulant substance in human urine, a process for its preparation and a pharmaceutical composition comprising the said substance for the prevention and/or treatment of diseases related to the disorders in blood coagulation system.

Abstract: A reagent for use in an immunoassay for measuring haptens, antigens or antibodies by means of a competitive binding method, which comprises a combination of an antibody and a labelled hapten or a labelled antigen or a combination of a hapten or an antigen and a labelled antibody, wherein the antibody and the labelled hapten or the labelled antigen in one combination or the hapten or the antigen and the labelled antibody in another combination are capable of undergoing reversible binding, and a device for use in an immunoassay wherein the reagent of the present invention is included in a single container. This immunoassay can be performed in a short time by the use of the immunoassay device of the present invention.

Abstract: The present invention relates to novel hydantoin derivatives, processes for producing said hydantoin derivatives, pharmaceutical compositions containing at least one of said hydantoin derivatives as aldose reductase inhibitors and novel intermediate compounds in the synthesis of said hydantoin derivatives.The present invention is based on the selection of a hydantoin which is bonded by a sulfonyl group to various substituents at the 1-position of the hydantoin skeleton.The compounds of the present invention have a strong inhibitory activity against aldose reductase. These compounds are extremely useful for the treatment and/or prevention of various forms of diabetic complications based on the accumulation of polyol metabolites.

Abstract: A method for measuring target substance contained in a liquid sample is disclosed. The measurement is carried out by using a device having at least one reaction area comprising a solid phase, and the liquid sample is applied onto the reaction area through a porous member to allow for a reaction of predetermined volume of the liquid sample on the reaction area. A device used for such measurement is also disclosed. A device comprises a body having at least one reaction area comprising a solid phase, and a porous member disposed on or above the reaction area. The porous member allows for the liquid sample to be permeated therethrough.

Abstract: This invention relates to a novel glycoprotein with anticoagulant activity in human urine, a process for its preparation and a pharmaceutical composition comprising the said glycoprotein for the prevention and/or treatment of diseases related to the disorders in the blood coagulation system.

Abstract: The present invention relates to novel hydantoin derivatives, processes for producing said hydantoin derivatives, pharmaceutical compositions containing at least one of said hydantoin derivatives as aldose reductase inhibitors and novel intermediate compounds in the synthesis of said hydantoin derivatives and pharmaceutical compositions containing at least one of hydantoin derivatives as hypoglycemic as well as hypolipidemic agents.The present invention is based on the selection of a hydantoin which is bonded by a sulfonyl group to various substituents at the 1-position of the hydantoin skeleton. The compounds of the present invention have a strong inhibitory activity against aldose reductase. These compounds are extremely useful for the treatment and/or prevention of various forms of diabetic complications based on the accumulation of polyol metabolites.The compounds of the present invention represent a satisfactory hypoglycemic as well as hypolipidemic activity.

Abstract: A system for automatically dispensing and diluting an accurate volume of a sample includes a nozzle tip removably mounted on a nozzle for collecting a predetermined volume of the sample. The nozzle includes an inner tube and an outer tube. The system also includes a sample pump for sucking and discharging the sample and the reagent into and out of the nozzle tip, a first three-way valve that is adapted to communicate the reagent bottle with the sample pump or the sample pump with the nozzle, and a plunger pump for sucking and discharging a liquid surface-detecting gas supplied from a gas source. A second three way valve is adapted to communicate the gas source with the plunger pump or the plunger pump with the nozzle, and a pressure sensor is positioned between the second three-way valve and the gas passage in the nozzle. Also, a two-way valve is positioned between the pressure sensor and the gas passage of the nozzle.

Abstract: An apparatus for reaction between a solid phase and a liquid phase of the present invention allows a tubular reaction vessel accommodating the liquid phase that reacts with the solid phase bound to the inside surface of said reaction vessel to hold in the peripheral region of a rotating element inclined with respect to the horizontal direction and also allows said tubular reaction vessel to repeat a predetermined number of cycles, each consisting at least of the steps of rotating continuously said rotating element in the inclined state at a predetermined constant speed for a predetermined time and loading/unloading said reaction vessel for the rest time of the rotating element. Because of these features, the apparatus of the present invention makes possible to have a simple construction which can be easily handled and can continuously promote the reaction in a plurality of the reaction vessels under identical reaction conditions for identical reaction time at a series of time.

Abstract: The present invention relates to novel 4,5-dihydro-6H-imidazo[4,5,1-ij]quinolin-6-one-6-oxime-O-sulfonic acid compounds, processes for producing said compounds, intermediate compounds, i.e. novel 4,5-dihydro-6H-imidazo[4,5,1-ij]quinolin-6-one compounds and 4,5-dihydro-6H-imidazo[4,5,1-ij]quinolin-6-one-6-oxime compounds in the synthesis of said compounds, processes for producing said intermediate compounds, and pharmaceutical or veterinary compositions containing said compounds.The present invention is based on the selection of the substituents of 4,5-dihydro-6H-imidazo[4,5,1-ij]-quinolin-6-one-6-oxime-O-sulfonic acid compounds at 2-position, namely 2-(2-penten-3-yl)-, 2-cyclohexyl-, 2-naphthyl-, 2-thienyl-, etc.The compounds of the present invention containing these substituents have potent hypotensive, anti-oedematous and diuretic effects as well as an activity of removing ascites. The compounds of the present invention are extremely useful for treatment of diseases and disorders mentioned above.

Abstract: A reaction vessel for microassay is provided. The reaction vessel has a body structure having provided therein at least one reaction unit having a channel having at least one fluid inlet and at least one reagent-immobilized area in the downstream of the fluid inlet. The channel is provided with a vent mechanism, and the reagent-immobilized area has a reagent fixedly immobilized thereto. The results of the assay are indicated in the reagent-immobilized area. The channel may be provided with a reagent-attached area wherein a reagent is tentatively attached so that the reagent may dissolve into the fluid flowing over the area. The channel may be also provided with a fluid sump for retaining the fluid within the reaction vessel. A rocking base allows the vessel to become inclined as the downstream sump moves downward when the fluid moves into the sump. By using the present reaction vessel, an assay at high precision may be carried out by a simple operation.

Abstract: The present invention relates to intermediate compounds to produce novel 1-acyl-2,3-dihydro-4(1H)-quinolinone-4-oxime derivatives with potent diuretic activity that can be used for treating and/or preventing hypertension, oedema and/or for removing ascites.The present invention is based on two characters. One is the selection of acyl substituents of 2,3-dihydro-4(1H)-quinolinone at 1-position, namely propionyl, t-butylcarbonyl, benzoyl, 2-bromobenzoyl, 4-chlorobenzoyl, 2-methylbenzoyl, 2-ethylbenzoyl, 2,3-dimethoxybenzoyl, 2,4-dichlorobenzoyl, 4-chloro-2-methyl benzoyl or 2-chloro-4-nitrobenzoyl. The other is the selection of substituents and positional specificity at 6- or 7-position, namely halogen atom, methoxy, trifluoromethyl or dimethylamino group.

Abstract: The present invention relates to novel cephalosporin derivatives, processes for preparing thereof, compositions for preventing and/or treating infectious diseases which comprise the novel cephalosporin derivatives as active components, and the intermediate compounds in the synthesis of cephalosporin derivatives and processes for producing thereof.The novel cephalosporin derivatives according to the present invention contain condensed heterocyclic groups, particularly a triazolopyrimidine ring or a thiadiazolopyrimidine ring as substituents at the 3-position of the cephem skeleton, and a hydroxyimino, an alkyloxyimino or an acyloxyimino moiety as substituents at the 7-position of the cephem skeleton.The compounds of the present invention containing the aforementioned substituents have a strong antibacterial activity against gram-negative bacteria and also against gram-positive bacteria including methicillin-resistant Staphylococcus aureus.

Abstract: The present invention relates to novel hydantoin derivatives, processes for producing said hydantoin derivatives, pharmaceutical compositions containing at least one of said hydantoin derivatives as aldose reductase inhibitors and novel intermediate compounds in the synthesis of said hydantoin derivatives.The present invention is based on the selection of a hydantoin which is bonded by a sulfonyl group to various substituents at the 1-position of the hydantoin skeleton.The compounds of the present invention have a strong inhibitory activity against aldose reductase. These compounds are extremely useful for the treatment and/or prevention of various forms of diabetic complications based on the accumulation of polyol metabolites.

Abstract: The present invention relates to novel cephalosporin derivatives, processes for preparing thereof, compositions for preventing and/or treating infectious diseases which comprise the novel cephalosporin derivatives as active components, and the intermediate compounds in the synthesis of cephalosporin derivatives and processes for producing thereof.The present invention is based on the selection of groups containing a condensed heterocyclic ring, particularly a triazolopyrimidine ring or a thiadiazolopyrimidine ring, as substituents at the 3-position of the cephem skeleton, and of groups containing a catechol moiety, particularly a catechol carboxymethyloxyimino moiety or a catechol carboxyimino moiety, as substituents at the 7-position of the cephem skeleton.The compounds of the present invention containing the aforementioned substituents have a strong antibacterial activity against Gram-negative bacteria and also against Gram-positive bacteria including methicillin-resistant Staphylococcus aureus.

Abstract: The present invention relates to novel 1-acyl-2,3-dihydro-4(1H)-quinolinone-4-oxime-O-sulfonic acid compound, processes for producing said compounds, intermediate compounds to produce said compounds and compositions containing said compounds with potent diuretic activity that can be used for treating and/or preventing hypertension, oedema and/or for removing ascites.The present invention is based on the selection of 1-acyl-7-halo-2,3-dihydro-4(1H)-quinolinone-4-oxime-O-sulfonic acid compounds, namely heterocyclic-or fused heterocyclic- carbonyl derivatives at 1 position.The compounds of the present invention containing these substituents have potent hypotensive, antioedematous and diuretic effect as well as an activity to remove ascites and are extremely useful for the treatment of diseases and disorders mentioned above.

Abstract: The present invention relates to novel hydantoin derivatives, processes for producing said hydantoin derivatives, pharmaceutical compositions containing at least one of said hydantoin derivatives as aldose reductase inhibitors and novel intermediate compounds in the synthesis of said hydantoin derivatives.The present invention is based on the selection of a hydantoin which is bonded by a sulfonyl group to various substituents at the 1-position of the hydantoin skeleton.The compounds of the present invention have a strong inhibitory activity against aldose reductase. These compounds are extremely useful for the treatment and/or prevention of various forms of diabetic complications based on the accumulation of polyol metabolites.